DK3580330T3 - Fremgangsmåde til generering af t-celleprogenitorer - Google Patents
Fremgangsmåde til generering af t-celleprogenitorer Download PDFInfo
- Publication number
- DK3580330T3 DK3580330T3 DK18704551.3T DK18704551T DK3580330T3 DK 3580330 T3 DK3580330 T3 DK 3580330T3 DK 18704551 T DK18704551 T DK 18704551T DK 3580330 T3 DK3580330 T3 DK 3580330T3
- Authority
- DK
- Denmark
- Prior art keywords
- generation
- cell progenitors
- progenitors
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305161 | 2017-02-13 | ||
| PCT/EP2018/053406 WO2018146297A1 (en) | 2017-02-13 | 2018-02-12 | Method for generating t cells progenitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3580330T3 true DK3580330T3 (da) | 2022-12-05 |
Family
ID=58185453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18704551.3T DK3580330T3 (da) | 2017-02-13 | 2018-02-12 | Fremgangsmåde til generering af t-celleprogenitorer |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20200046767A1 (enExample) |
| EP (2) | EP3580330B1 (enExample) |
| JP (2) | JP7164798B2 (enExample) |
| KR (1) | KR102666158B1 (enExample) |
| CN (1) | CN110506110B (enExample) |
| AU (1) | AU2018217404B2 (enExample) |
| BR (1) | BR112019016672A8 (enExample) |
| CA (1) | CA3053294A1 (enExample) |
| DK (1) | DK3580330T3 (enExample) |
| ES (1) | ES2931530T3 (enExample) |
| HU (1) | HUE060548T2 (enExample) |
| IL (1) | IL268641B2 (enExample) |
| MA (1) | MA47541A (enExample) |
| PL (1) | PL3580330T3 (enExample) |
| PT (1) | PT3580330T (enExample) |
| WO (1) | WO2018146297A1 (enExample) |
| ZA (1) | ZA201905470B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2931530T3 (es) * | 2017-02-13 | 2022-12-30 | Hopitaux Paris Assist Publique | Método para generar progenitores de células T |
| CA3077344A1 (en) * | 2017-09-29 | 2019-04-04 | Regents Of The University Of Minnesota | Methods of making, expanding, and using a human progenitor t cell |
| EP3700334B1 (en) | 2017-10-27 | 2026-04-08 | Immunebridge Inc. | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene |
| CA3091158A1 (en) | 2018-02-14 | 2019-08-22 | Sunnybrook Research Institute | Method for generating cells of the t cell lineage |
| EP3847243A1 (en) * | 2018-09-07 | 2021-07-14 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| WO2020223517A1 (en) * | 2019-05-01 | 2020-11-05 | Transfusion Health, Llc | Methods of making oligopotent and unipotent precursors |
| CA3144640A1 (en) * | 2019-06-24 | 2020-12-30 | Children's Hospital Los Angeles | Bcl11b overexpression to enhance human thymopoiesis and t cell function |
| EP4058562A4 (en) * | 2019-11-14 | 2023-12-20 | Zandstra, Peter William | MEDIA FORMULATIONS AND PROCESSES FOR PRODUCING PROGENITOR T CELLS |
| WO2021200901A1 (ja) * | 2020-03-31 | 2021-10-07 | 国立大学法人京都大学 | Ｔ前駆細胞の製造方法 |
| CN116615461A (zh) | 2020-11-30 | 2023-08-18 | 醣基生医股份有限公司 | 用于富集细胞的抗体 |
| CA3209946A1 (en) * | 2021-03-05 | 2022-09-09 | Matthew Angel | Engineered immune cell therapies |
| EP4347793A1 (en) * | 2021-05-25 | 2024-04-10 | Universiteit Gent | Generating t cell precursors via agonizing tumor necrosis factor receptor 2 |
| US20260152721A1 (en) | 2021-11-04 | 2026-06-04 | Aphp (Assistance Publique - Hôpitaux De Paris) | Method for generating nk cells |
| FR3130843A1 (fr) * | 2021-12-21 | 2023-06-23 | Universite Claude Bernard Lyon 1 | Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt |
| KR20250150555A (ko) | 2023-01-27 | 2025-10-20 | 노치 테라퓨틱스 (캐나다) 인크. | 줄기세포/전구세포로부터 t 세포 계통 모집단을 생성하는 방법 |
| KR20250152088A (ko) * | 2023-02-22 | 2025-10-22 | 메이라지티엑스 셀 테라피스 | 흉선 재생 방법 |
| US20250332260A1 (en) | 2024-04-10 | 2025-10-30 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025219552A1 (en) | 2024-04-17 | 2025-10-23 | Assitance Publique Hopitaux De Paris | Method for producing t cell progenitors from human pluripotent stem cells |
| CN121969764A (zh) * | 2024-08-29 | 2026-05-01 | 京东方科技集团股份有限公司 | 引物设计、疾病分型诊断方法及装置、组合物、试剂盒及其用途 |
| CN119709836B (zh) * | 2024-12-21 | 2025-08-08 | 湖南农业大学 | OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| WO1999028486A1 (en) | 1997-12-04 | 1999-06-10 | Duke University | Methods of isolating and using cd7+cd34-lin-hematopoietic cells |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| CA2737193A1 (en) | 2008-09-12 | 2010-03-18 | Universidade Federal De Sao Paulo - Unifesp | Ischemic tissue cell therapy |
| US8772028B2 (en) * | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| US8871510B2 (en) | 2009-12-03 | 2014-10-28 | University Of Utah Research Foundation | Methods for generating T lymphocytes from hematopoietic stem cells |
| EP3590520B1 (en) | 2010-04-09 | 2021-12-29 | Fred Hutchinson Cancer Research Center | Compositions for providing hematopoietic function without hla matching |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| WO2013086436A1 (en) * | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| US20150352180A1 (en) | 2013-01-11 | 2015-12-10 | The Trustee Of The University Of Pennsylvania | Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation |
| EP3027755B1 (en) * | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20170128556A1 (en) | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| JP6661544B2 (ja) * | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したｔ細胞の自動生成法 |
| WO2016039933A1 (en) | 2014-09-11 | 2016-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral vector for treating hemoglobin disorders |
| FR3026744B1 (fr) * | 2014-10-06 | 2024-04-19 | Hopitaux Paris Assist Publique | Methode de generation de progeniteurs de cellules t |
| US11555207B2 (en) * | 2015-06-17 | 2023-01-17 | The Uab Research Foundation | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| US12076342B2 (en) | 2016-04-08 | 2024-09-03 | The Governing Council Of The University Of Toronto | Method for generating progenitor t cells from stem and/or progenitor cells and use of same |
| ES2931530T3 (es) * | 2017-02-13 | 2022-12-30 | Hopitaux Paris Assist Publique | Método para generar progenitores de células T |
-
2018
- 2018-02-12 ES ES18704551T patent/ES2931530T3/es active Active
- 2018-02-12 EP EP18704551.3A patent/EP3580330B1/en active Active
- 2018-02-12 IL IL268641A patent/IL268641B2/en unknown
- 2018-02-12 CN CN201880024963.1A patent/CN110506110B/zh active Active
- 2018-02-12 EP EP22158116.8A patent/EP4067482A1/en active Pending
- 2018-02-12 US US16/485,488 patent/US20200046767A1/en not_active Abandoned
- 2018-02-12 MA MA047541A patent/MA47541A/fr unknown
- 2018-02-12 HU HUE18704551A patent/HUE060548T2/hu unknown
- 2018-02-12 BR BR112019016672A patent/BR112019016672A8/pt unknown
- 2018-02-12 PT PT187045513T patent/PT3580330T/pt unknown
- 2018-02-12 PL PL18704551.3T patent/PL3580330T3/pl unknown
- 2018-02-12 WO PCT/EP2018/053406 patent/WO2018146297A1/en not_active Ceased
- 2018-02-12 CA CA3053294A patent/CA3053294A1/en active Pending
- 2018-02-12 DK DK18704551.3T patent/DK3580330T3/da active
- 2018-02-12 AU AU2018217404A patent/AU2018217404B2/en active Active
- 2018-02-12 KR KR1020197024529A patent/KR102666158B1/ko active Active
- 2018-02-12 JP JP2019565052A patent/JP7164798B2/ja active Active
-
2019
- 2019-08-19 ZA ZA2019/05470A patent/ZA201905470B/en unknown
-
2020
- 2020-09-02 US US17/010,208 patent/US11426430B2/en active Active
-
2021
- 2021-02-11 US US17/173,668 patent/US11642376B2/en active Active
- 2021-02-11 US US17/173,632 patent/US11638723B2/en active Active
-
2022
- 2022-09-28 JP JP2022154550A patent/JP2022185024A/ja active Pending
-
2023
- 2023-04-06 US US18/296,623 patent/US20230293586A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3500664T3 (da) | Fremgangsmåde til differentiering af pluripotente celler | |
| DK3444334T3 (da) | Fremgangsmåde til inducering af CD8+ T-celler | |
| DK3636753T3 (da) | Fremgangsmåde til fremstilling af DNA-redigeret eukaryotisk celle | |
| DK3116902T3 (da) | Fremgangsmåde til generering af T-celler kompatible for allogen transplantation | |
| IL260101B (en) | Generating simulated output for a specimen | |
| DK3402773T3 (da) | Fremgangsmåde til fremstilling af methanol | |
| DK3292134T3 (da) | Metode til dyrkning af akkermansia | |
| DK3285784T3 (da) | Fremgangsmåde til fremstilling af en prøve af fækal mikrobiota | |
| DK3460102T3 (da) | Fremgangsmåde til fremstilling af en elektrokatalysator | |
| DK3665173T3 (da) | Ny fremgangsmåde til yntetisering af amanitiner | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3661562T3 (da) | Fremgangsmåde til konjugation af cys-mabs | |
| DK3487443T3 (da) | Fremgangsmåde til opmåling af en implantat-implantat-situation | |
| DK3423714T3 (da) | Fremgangsmåde til generering af elektricitet | |
| DK3210276T3 (da) | Fremgangsmåde til drift af et uafhængigt netværk | |
| DK3622081T3 (da) | Fremgangsmåde til fremstilling af en azaphilon i talaromyces atroroseus | |
| DK4235628T3 (da) | System til frembringelse af en omgivelse | |
| IL275288B1 (en) | Methods for obtaining muscle-derived cells | |
| DK3625236T3 (da) | Fremgangsmåde til fremstilling af et optisk aktivt cineolderivat | |
| DK3347481T3 (da) | Fremgangsmåde til oprensning af biomassehydrolysat | |
| DK3275211T3 (da) | Fremgangsmåde til drift af et elektroakustisk system samt et elektroakustisk system | |
| DK3548427T3 (da) | Fremgangsmåde til fremstilling af hydrogen | |
| DK3224894T3 (da) | Fremgangsmåde til symmetrering af et energilagersystem | |
| DK3331986T3 (da) | Fremgangsmåde til fremstilling af celledyrkningsmedium | |
| DK3733865T3 (da) | Fremgangsmåde til opnåelse af encellet mrna-sekvens |